Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin versus investigator's choice chemotherapy in relapsed or refractory CD22-positive acute lymphoblastic leukemia
2011-005491-41Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Pfizer. Started May 2012; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2011-005491-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005491-41.